INHIBITORY ACTIVITY OF INDONESIAN MICROBIAL EXTRACTS AGAINST PROLIFERATION OF DLD-1 COLORECTAL CANCER CELL LINE

Ariza Yandwiputra Besari (Research Center for Vaccine and Drug, National Research and Innovation Agency (BRIN))
Danang Waluyo (Research Center for Vaccine and Drug, National Research and Innovation Agency (BRIN))
Tinta Komariyah (Research Center for Vaccine and Drug, National Research and Innovation Agency (BRIN))
Erwahyuni Endang Prabandari (Research Center for Vaccine and Drug, National Research and Innovation Agency (BRIN))

Jurnal Bioteknologi & Biosains Indonesia (JBBI)
Vol. 10 No. 1 (2023): Juni 2023

Colorectal cancer (CRC) is the second deadliest cancer in the world. Several anti-cancer agents are currently used for the clinical treatment of CRC. However, toxicity and drug resistance pose significant challenges in CRC chemotherapy. On the other hand, microbe-derived natural products have been explored as a source for the development of anti-cancer therapeutic agents. This study aimed to examine the potential of the microbial library in BioMCC (Biotech Center-BPPT Microbial Culture Collection) as a source for anti-cancer drug discovery. Among the 720 fungal extracts tested, 60 extracts (8.3%) showed inhibitory activity against the proliferation of the colorectal carcinoma DLD-1 cell line, while not affecting Vero cells (African green monkey kidney normal cell line). One of these active extracts was derived from the fungus Sporothrix sp. BioMCC-f.T.7716. Although the inhibitory mechanism of this extract against the proliferation of the DLD-1 cell line could not be determined, this study clearly demonstrated the potential use of Indonesian microbial extracts as a source for the discovery of anti-cancer agents.